
Opinion|Videos|April 3, 2025
Advancing From Topicals to Systemic Treatment in Psoriasis Management
Panelists discuss how undertreatment in psoriasis persists despite expanded therapeutic options due to multiple barriers including limited physician awareness of disease impact, insurance restrictions, socioeconomic disparities, patient concerns about medication safety, inadequate screening for comorbidities like psoriatic arthritis, outdated treatment paradigms, health care access challenges, and the failure to recognize that even limited disease in high-impact areas may warrant systemic therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some potential reasons for undertreatment in psoriasis despite a wide range of available treatment options in recent years?
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH
2
Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH
3
Microneedle Stamp Enters Phase 1 Trial for Peanut Allergy Immunotherapy
4
Ketamine, Psychedelics Share Neuroimmune Signature in TRD
5








































































